Cebon, J. S., Gore, M., Thompson, J. F., Davis, I. D., McArthur, G. A., Walpole, E., . . . Chen, W. (2020). Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. J Immunother Cancer.
Citación estilo ChicagoCebon, Jonathan S., et al. "Results of a Randomized, Double-blind Phase II Clinical Trial of NY-ESO-1 Vaccine With ISCOMATRIX Adjuvant Versus ISCOMATRIX Alone in Participants With High-risk Resected Melanoma." J Immunother Cancer 2020.
Cita MLACebon, Jonathan S., et al. "Results of a Randomized, Double-blind Phase II Clinical Trial of NY-ESO-1 Vaccine With ISCOMATRIX Adjuvant Versus ISCOMATRIX Alone in Participants With High-risk Resected Melanoma." J Immunother Cancer 2020.